Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT06417008 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06417008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06417008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 28, 2024
Completion date
June 1, 2030
Enrollment
1,080 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer